View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBiodexa Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6핵심 정보4.31%순이익 성장률61.23%주당순이익(EPS) 성장률Biotechs 산업 성장률11.51%매출 성장률-14.02%자기자본이익률-71.65%순이익률-832.09%최근 순이익 업데이트30 Jun 2022최근 과거 실적 업데이트Reported Earnings • Sep 15First half 2022 earnings released: UK£0.031 loss per share (vs UK£0.05 loss in 1H 2021)First half 2022 results: UK£0.031 loss per share (improved from UK£0.05 loss in 1H 2021). Net loss: UK£3.06m (loss narrowed 2.9% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 27Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: UK£0.07 loss per share (up from UK£0.52 loss in FY 2020). Net loss: UK£5.46m (loss narrowed 75% from FY 2020). Revenue missed analyst estimates by 9.6%. Earnings per share (EPS) exceeded analyst estimates by 12%. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 20First half 2021 earnings released: UK£0.05 loss per share (vs UK£0.64 loss in 1H 2020)First half 2021 results: Net loss: UK£3.15m (loss narrowed 82% from 1H 2020).모든 업데이트 보기Recent updates공고 • Feb 04Midatech Pharma Announces Receipt of NASDAQ NoticeMidatech Pharma plc announced that it received written notification from The NASDAQ Stock Market LLC, dated 31 January 2023, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's American Depositary Shares (the "Depositary Shares"), each representing 25 ordinary shares of the Company, for the 30 consecutive business days beginning14 December2022, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing of the Depositary Shares, and they will continue to trade on The NASDAQ Capital Market under the symbol "MTP." In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until 31 July 2023 (the "Compliance Period"), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Depositary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the Compliance Period. If the Depositary Shares do not regain compliance with the minimum bid price requirement during the Compliance Period, the Company may be eligible for an additional grace period of 180 calendar days provided that the Company satisfies NASDAQ's initial listing standards for listing on The NASDAQ Capital Market, other than the minimum bid price requirement, and provides written notice to NASDAQ of its intention to cure the delinquency during the second grace period. If the Company does not regain compliance during the initial grace period and is not eligible for an additional grace period, NASDAQ will provide written notice that the Depositary Shares are subject to delisting from The NASDAQ Capital Market. In that event, the Company may appeal such determination to a hearing panel. The Company intends to monitor the bid price of its Depositary Shares during the Compliance Period and will consider taking such actions as may be necessary and appropriate to achieve compliance with continued listing requirements prior to the expiration of all available grace periods. The Company's business operations are not affected by the receipt of the Notification Letter. The Company's ordinary shares are admitted to trading on the AIM Market of the London Stock Exchange, and the Notification Letter does not affect the Company's compliance status with the AIM Rules for Companies.공고 • Jan 12Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 StudyMidatech Pharma PLC announced that following completion of one month of treatment with MTX-110 in the first patient, its Phase I study of MTX-110 in recurrent glioblastoma (rGB) (NCT 05324501) will continue with a planned dose escalation following a positive recommendation from the study's Data Safety Monitoring Board (DSMB). The Phase I study, the MAGIC-G1 study, is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX-110 administered by convection enhanced delivery (CED) via implanted refillable pump and catheter. The study aims to recruit two cohorts, each with a minimum of four patients; the first cohort will receive MTX-110 only and the second cohort will receive MTX-110 in combination with lomustine. The first patient in the study was dosed at 60uM of MTX-110 via direct-to-tumour delivery and has received four 48-hour infusions over a period of four weeks. No treatment-associated adverse events were noted in the patient during this period. Following successful completion of the first month of treatment, the DSMB reviewed the available data on 11 January 2023 and recommended dose escalation in the study to 90uM. This dose is expected to be the optimal one of MTX-110 and is the one currently being used in the ongoing Phase I study of patients with diffuse intrinsic pontine glioma (DIPG) at the Columbia University, USA. Patient 1 continues treatment as per the study protocol and patient 2 is expected to start treatment by the end of January 2023 and will receive the 90uM dose. GB is the most common and devastating primary malignant brain tumour in adults encompassing 14.3% of all primary brain and central nervous system neoplasms. With an incidence of approximately 3.2 per 100,000 population in the USA, approximately 12,300 people in the USA will be diagnosed with GB per annum. Standard of care for treatment of GB is typically maximal surgical resection followed by radiotherapy plus concomitant and maintenance temozolomide chemotherapy with or without the Optune® device. Notwithstanding, the multidisciplinary approach, almost all patients experience tumour progression with nearly universal mortality. The median survival from initial diagnosis is less than 21 months. Currently, no standard of care is established for rGB. MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-ß-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favorable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient derived DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559).Reported Earnings • Sep 15First half 2022 earnings released: UK£0.031 loss per share (vs UK£0.05 loss in 1H 2021)First half 2022 results: UK£0.031 loss per share (improved from UK£0.05 loss in 1H 2021). Net loss: UK£3.06m (loss narrowed 2.9% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 27Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: UK£0.07 loss per share (up from UK£0.52 loss in FY 2020). Net loss: UK£5.46m (loss narrowed 75% from FY 2020). Revenue missed analyst estimates by 9.6%. Earnings per share (EPS) exceeded analyst estimates by 12%. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 20First half 2021 earnings released: UK£0.05 loss per share (vs UK£0.64 loss in 1H 2020)First half 2021 results: Net loss: UK£3.15m (loss narrowed 82% from 1H 2020).분석 기사 • May 17Here's Why Midatech Pharma (LON:MTPH) Must Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...분석 기사 • Feb 24Midatech Pharma plc (LON:MTPH) Insiders Have Been SellingWe often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...Is New 90 Day High Low • Feb 11New 90-day high: UK£0.42The company is up 65% from its price of UK£0.26 on 12 November 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 26% over the same period.Is New 90 Day High Low • Jan 23New 90-day high: UK£0.34The company is up 15% from its price of UK£0.29 on 23 October 2020. The British market is also up 15% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Biotechs industry, which is up 15% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: UK£0.27The company is down 19% from its price of UK£0.34 on 31 July 2020. The British market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.매출 및 비용 세부 내역Biodexa Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이AIM:BDRX 매출, 비용 및 순이익 (GBP Millions)날짜매출순이익일반관리비연구개발비30 Jun 221-53031 Mar 221-53031 Dec 211-53030 Sep 211-73230 Jun 211-83231 Mar 210-154131 Dec 200-224030 Jun 200-225031 Mar 201-165031 Dec 191-94030 Jun 192-94031 Mar 192-104031 Dec 182-104030 Jun 181-114031 Mar 181-114031 Dec 171-124030 Sep 17-3-1-7-530 Jun 174-1810631 Mar 176-1914731 Dec 161-63030 Sep 165-17121030 Jun 164-13136양질의 수익: BDRX 은(는) 현재 수익성이 없습니다.이익 마진 증가: BDRX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BDRX는 수익성이 없지만 지난 5년 동안 연평균 4.3%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BDRX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BDRX은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(1.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BDRX는 현재 수익성이 없으므로 자본 수익률이 음수(-71.65%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/04/27 03:48종가2023/04/25 00:00수익2022/06/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biodexa Pharmaceuticals Plc는 3명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Aydin HuseynovLadenburg Thalmann & CompanyJens LindqvistSinger Capital MarketsDavid BautzZacks Small-Cap Research
Reported Earnings • Sep 15First half 2022 earnings released: UK£0.031 loss per share (vs UK£0.05 loss in 1H 2021)First half 2022 results: UK£0.031 loss per share (improved from UK£0.05 loss in 1H 2021). Net loss: UK£3.06m (loss narrowed 2.9% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 27Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: UK£0.07 loss per share (up from UK£0.52 loss in FY 2020). Net loss: UK£5.46m (loss narrowed 75% from FY 2020). Revenue missed analyst estimates by 9.6%. Earnings per share (EPS) exceeded analyst estimates by 12%. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 20First half 2021 earnings released: UK£0.05 loss per share (vs UK£0.64 loss in 1H 2020)First half 2021 results: Net loss: UK£3.15m (loss narrowed 82% from 1H 2020).
공고 • Feb 04Midatech Pharma Announces Receipt of NASDAQ NoticeMidatech Pharma plc announced that it received written notification from The NASDAQ Stock Market LLC, dated 31 January 2023, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's American Depositary Shares (the "Depositary Shares"), each representing 25 ordinary shares of the Company, for the 30 consecutive business days beginning14 December2022, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing of the Depositary Shares, and they will continue to trade on The NASDAQ Capital Market under the symbol "MTP." In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until 31 July 2023 (the "Compliance Period"), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Depositary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the Compliance Period. If the Depositary Shares do not regain compliance with the minimum bid price requirement during the Compliance Period, the Company may be eligible for an additional grace period of 180 calendar days provided that the Company satisfies NASDAQ's initial listing standards for listing on The NASDAQ Capital Market, other than the minimum bid price requirement, and provides written notice to NASDAQ of its intention to cure the delinquency during the second grace period. If the Company does not regain compliance during the initial grace period and is not eligible for an additional grace period, NASDAQ will provide written notice that the Depositary Shares are subject to delisting from The NASDAQ Capital Market. In that event, the Company may appeal such determination to a hearing panel. The Company intends to monitor the bid price of its Depositary Shares during the Compliance Period and will consider taking such actions as may be necessary and appropriate to achieve compliance with continued listing requirements prior to the expiration of all available grace periods. The Company's business operations are not affected by the receipt of the Notification Letter. The Company's ordinary shares are admitted to trading on the AIM Market of the London Stock Exchange, and the Notification Letter does not affect the Company's compliance status with the AIM Rules for Companies.
공고 • Jan 12Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 StudyMidatech Pharma PLC announced that following completion of one month of treatment with MTX-110 in the first patient, its Phase I study of MTX-110 in recurrent glioblastoma (rGB) (NCT 05324501) will continue with a planned dose escalation following a positive recommendation from the study's Data Safety Monitoring Board (DSMB). The Phase I study, the MAGIC-G1 study, is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX-110 administered by convection enhanced delivery (CED) via implanted refillable pump and catheter. The study aims to recruit two cohorts, each with a minimum of four patients; the first cohort will receive MTX-110 only and the second cohort will receive MTX-110 in combination with lomustine. The first patient in the study was dosed at 60uM of MTX-110 via direct-to-tumour delivery and has received four 48-hour infusions over a period of four weeks. No treatment-associated adverse events were noted in the patient during this period. Following successful completion of the first month of treatment, the DSMB reviewed the available data on 11 January 2023 and recommended dose escalation in the study to 90uM. This dose is expected to be the optimal one of MTX-110 and is the one currently being used in the ongoing Phase I study of patients with diffuse intrinsic pontine glioma (DIPG) at the Columbia University, USA. Patient 1 continues treatment as per the study protocol and patient 2 is expected to start treatment by the end of January 2023 and will receive the 90uM dose. GB is the most common and devastating primary malignant brain tumour in adults encompassing 14.3% of all primary brain and central nervous system neoplasms. With an incidence of approximately 3.2 per 100,000 population in the USA, approximately 12,300 people in the USA will be diagnosed with GB per annum. Standard of care for treatment of GB is typically maximal surgical resection followed by radiotherapy plus concomitant and maintenance temozolomide chemotherapy with or without the Optune® device. Notwithstanding, the multidisciplinary approach, almost all patients experience tumour progression with nearly universal mortality. The median survival from initial diagnosis is less than 21 months. Currently, no standard of care is established for rGB. MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-ß-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favorable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient derived DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559).
Reported Earnings • Sep 15First half 2022 earnings released: UK£0.031 loss per share (vs UK£0.05 loss in 1H 2021)First half 2022 results: UK£0.031 loss per share (improved from UK£0.05 loss in 1H 2021). Net loss: UK£3.06m (loss narrowed 2.9% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 27Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: UK£0.07 loss per share (up from UK£0.52 loss in FY 2020). Net loss: UK£5.46m (loss narrowed 75% from FY 2020). Revenue missed analyst estimates by 9.6%. Earnings per share (EPS) exceeded analyst estimates by 12%. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 20First half 2021 earnings released: UK£0.05 loss per share (vs UK£0.64 loss in 1H 2020)First half 2021 results: Net loss: UK£3.15m (loss narrowed 82% from 1H 2020).
분석 기사 • May 17Here's Why Midatech Pharma (LON:MTPH) Must Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • Feb 24Midatech Pharma plc (LON:MTPH) Insiders Have Been SellingWe often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Is New 90 Day High Low • Feb 11New 90-day high: UK£0.42The company is up 65% from its price of UK£0.26 on 12 November 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 26% over the same period.
Is New 90 Day High Low • Jan 23New 90-day high: UK£0.34The company is up 15% from its price of UK£0.29 on 23 October 2020. The British market is also up 15% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Biotechs industry, which is up 15% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: UK£0.27The company is down 19% from its price of UK£0.34 on 31 July 2020. The British market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period.